• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Voyager Therapeutics Inc.

    11/14/25 3:47:55 PM ET
    $VYGR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $VYGR alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 5)


    Voyager Therapeutics, Inc.

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    92915B106

    (CUSIP Number)


    09/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    92915B106


    1Names of Reporting Persons

    EcoR1 Capital, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,003,636.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,003,636.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,003,636.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.8 %
    12Type of Reporting Person (See Instructions)

    IA, OO

    Comment for Type of Reporting Person:  Percentage calculated based on (1) 670,303 shares of Common Stock beneficially owned by the reporting person and warrants to acquire 3,333,333 shares of Common Stock beneficially owned by the reporting person, and (2) 55,600,084 shares of Common Stock outstanding on November 3, 2025, as reported in the Form 10-Q filed by the Issuer for the quarter ended September 30, 2025.


    SCHEDULE 13G

    CUSIP No.
    92915B106


    1Names of Reporting Persons

    Oleg Nodelman
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,003,636.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,003,636.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,003,636.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.8 %
    12Type of Reporting Person (See Instructions)

    HC, IN

    Comment for Type of Reporting Person:  Percentage calculated based on (1) 670,303 shares of Common Stock beneficially owned by the reporting person and warrants to acquire 3,333,333 shares of Common Stock beneficially owned by the reporting person, and (2) 55,600,084 shares of Common Stock outstanding on November 3, 2025, as reported in the Form 10-Q filed by the Issuer for the quarter ended September 30, 2025.


    SCHEDULE 13G

    CUSIP No.
    92915B106


    1Names of Reporting Persons

    EcoR1 Capital Fund Qualified, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    3,738,856.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    3,738,856.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,738,856.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.4 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:  Percentage calculated based on (1) 594,523 shares of Common Stock beneficially owned by the reporting person and warrants to acquire 3,144,333 shares of Common Stock beneficially owned by the reporting person, and (2) 55,600,084 shares of Common Stock outstanding on November 3, 2025, as reported in the Form 10-Q filed by the Issuer for the quarter ended September 30, 2025.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Voyager Therapeutics, Inc.
    (b)Address of issuer's principal executive offices:

    75 Hayden Avenue, Lexington, MA 02421
    Item 2. 
    (a)Name of person filing:

    EcoR1 Capital, LLC, a Delaware limited liability company ("EcoR1") EcoR1 Capital Fund Qualified, L.P., a Delaware limited partnership ("Qualified Fund") Oleg Nodelman Qualified Fund is filing this statement jointly with the other reporting persons, but not as a member of a group, and it expressly disclaims membership in a group. In addition, the filing of this Schedule 13G on behalf of Qualified Fund should not be construed as an admission that it is, and it disclaims that it is, a beneficial owner, as defined in Rule 13d-3 under the Act, of any securities covered by this Schedule 13G. Each reporting person also disclaims beneficial ownership of the securities reported herein except to the extent of that person's pecuniary interest therein.
    (b)Address or principal business office or, if none, residence:

    357 Tehama Street #3 San Francisco, CA 94103
    (c)Citizenship:

    See Item 4 of the cover sheet for each reporting person.
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    92915B106
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    EcoR1: 4,003,636 Oleg Nodelman: 4,003,636 Qualified Fund: 3,738,856
    (b)Percent of class:

    EcoR1: 6.8% Oleg Nodelman: 6.8% Qualified Fund: 6.4%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    EcoR1: 0 Oleg Nodelman: 0 Qualified Fund: 0

     (ii) Shared power to vote or to direct the vote:

    EcoR1: 4,003,636 Oleg Nodelman: 4,003,636 Qualified Fund: 3,738,856

     (iii) Sole power to dispose or to direct the disposition of:

    EcoR1: 0 Oleg Nodelman: 0 Qualified Fund: 0

     (iv) Shared power to dispose or to direct the disposition of:

    EcoR1: 4,003,636 Oleg Nodelman: 4,003,636 Qualified Fund: 3,738,856

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.


    EcoR1 is the general partner and investment adviser of investment funds, including Qualified Fund. Mr. Nodelman is the control person of EcoR1.
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    EcoR1 Capital, LLC
     
    Signature:/s/ Oleg Nodelman
    Name/Title:Manager
    Date:11/14/2025
     
    Oleg Nodelman
     
    Signature:/s/ Oleg Nodelman
    Name/Title:Reporting person
    Date:11/14/2025
     
    EcoR1 Capital Fund Qualified, L.P.
     
    Signature:/s/ Oleg Nodelman
    Name/Title:Manager of the General Partner, EcoR1 Capital, LLC
    Date:11/14/2025
    Exhibit Information

    Exhibit 99 - Agreement Regarding Joint Filing of Statement on Schedule 13D or 13G

    Get the next $VYGR alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VYGR

    DatePrice TargetRatingAnalyst
    1/10/2025Overweight
    Cantor Fitzgerald
    12/2/2024$12.00Buy
    Citigroup
    11/29/2024$7.00 → $11.00Outperform
    Wedbush
    10/16/2024$15.00Outperform
    Leerink Partners
    3/26/2024$22.00Buy
    Guggenheim
    3/19/2024$30.00Buy
    H.C. Wainwright
    3/7/2024$16.00Buy
    Citigroup
    1/2/2024$14.00Equal Weight → Overweight
    Wells Fargo
    More analyst ratings

    $VYGR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cantor Fitzgerald initiated coverage on Voyager Therapeutics

    Cantor Fitzgerald initiated coverage of Voyager Therapeutics with a rating of Overweight

    1/10/25 9:15:32 AM ET
    $VYGR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Citigroup initiated coverage on Voyager Therapeutics with a new price target

    Citigroup initiated coverage of Voyager Therapeutics with a rating of Buy and set a new price target of $12.00

    12/2/24 7:04:18 AM ET
    $VYGR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Wedbush resumed coverage on Voyager Therapeutics with a new price target

    Wedbush resumed coverage of Voyager Therapeutics with a rating of Outperform and set a new price target of $11.00 from $7.00 previously

    11/29/24 7:27:18 AM ET
    $VYGR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $VYGR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Voyager Reports Third Quarter 2025 Financial and Operating Results

    - Momentum building around tau: expect VY7523 clinical data and VY1706 clinical entry in 2026 -  - Sharpened focus on multi-modality pipeline with introduction of Voyager NeuroShuttle™ discovery program and small molecule collaboration - - Ended 3Q25 with cash position of $229 million, maintaining runway into 2028 - LEXINGTON, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today reported third quarter 2025 financial and operating results. "Voyager continues to seek out the optimal modalities for each neurotherapeutic target we pursue. During the

    11/10/25 8:01:00 AM ET
    $VYGR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Transition Bio and Voyager Announce Collaboration to Advance Small Molecules Targeting TDP-43 in ALS and Frontotemporal Dementia

    CAMBRIDGE, United Kingdom and LEXINGTON, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Transition Bio, a drug discovery company focused on unlocking traditionally "undruggable" targets by leveraging biomolecular condensates, and Voyager Therapeutics (NASDAQ:VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, have entered into a drug discovery collaboration and license option agreement. The companies will collaborate to discover and develop novel, selective small molecules for people suffering from amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) with TDP-43 pathology. TDP-43 pathology is common in many neurodegenerative diseases,

    11/10/25 8:01:00 AM ET
    $VYGR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Voyager to Present at Upcoming Investor Conferences

    LEXINGTON, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced that the company will participate in the following upcoming investor conferences: Citi's 2025 Biopharma Back to School Conference: Fireside chat at 4:00 p.m. ET on Tuesday, September 2, 2025, in Boston, MA, during which the company plans to highlight preclinical data supporting its non-viral delivery platform leveraging novel receptor-binding molecules to transport multiple modalities of neurotherapeutics across the blood-brain barrier.2025 Wells Fargo Healthcare Conference: Fireside chat

    8/26/25 7:00:00 AM ET
    $VYGR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $VYGR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Jorgensen Nathan D. sold $36,643 worth of shares (7,666 units at $4.78), decreasing direct ownership by 6% to 123,834 units (SEC Form 4)

    4 - Voyager Therapeutics, Inc. (0001640266) (Issuer)

    10/7/25 4:30:38 PM ET
    $VYGR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Medical Officer Ferguson Toby sold $70,870 worth of shares (19,000 units at $3.73), decreasing direct ownership by 12% to 138,914 units (SEC Form 4)

    4 - Voyager Therapeutics, Inc. (0001640266) (Issuer)

    8/20/25 2:09:54 PM ET
    $VYGR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Vitale Nancy

    4 - Voyager Therapeutics, Inc. (0001640266) (Issuer)

    6/4/25 9:09:17 PM ET
    $VYGR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $VYGR
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Voyager Therapeutics Inc.

    SCHEDULE 13G/A - Voyager Therapeutics, Inc. (0001640266) (Subject)

    11/14/25 6:30:26 PM ET
    $VYGR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Voyager Therapeutics Inc.

    SCHEDULE 13G/A - Voyager Therapeutics, Inc. (0001640266) (Subject)

    11/14/25 3:47:55 PM ET
    $VYGR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form S-3 filed by Voyager Therapeutics Inc.

    S-3 - Voyager Therapeutics, Inc. (0001640266) (Filer)

    11/10/25 4:02:32 PM ET
    $VYGR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $VYGR
    Financials

    Live finance-specific insights

    View All

    Voyager Presents Robust Preclinical Data from Tau Targeting Gene Therapy and Antibody Programs at AD/PD™ 2025

    - Single IV administration of tau silencing gene therapy VY1706 significantly reduced tau mRNA and protein levels, with broad brain distribution and liver de-targeting, in NHP study - - Preclinical murine data strengthen case for specifically targeting pathologic forms of tau with the clinical-stage anti-tau antibody VY7523 - - Voyager to host live webcast on April 7 recapping key AD/PD™ 2025 data - LEXINGTON, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today reported new data from its two preclinical programs targeting tau for the treatment of Alzheimer's di

    3/31/25 7:00:47 AM ET
    $VYGR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Voyager Reports Fourth Quarter and Full Year 2024 Financial and Operating Results

    - Tau silencing gene therapy VY1706 robustly reduced tau mRNA levels, with broad distribution, and was well-tolerated in NHP study; IND filing anticipated in 2026 - - Anti-tau antibody VY7523 was well tolerated in healthy volunteers and showed dose-proportional pharmacokinetics; initial tau PET imaging data in Alzheimer's patients expected H2 2026 - LEXINGTON, Mass., March 11, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today reported fourth quarter and full year 2024 financial and operating results. "Over the past year, Voyager has significantly advanced our two wholly-

    3/11/25 4:01:00 PM ET
    $VYGR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Voyager Therapeutics Announces Fourth Quarter 2024 Conference Call and Webcast

    LEXINGTON, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it will report fourth quarter 2024 financial and operating results after market close on Tuesday, March 11, 2025. Subsequently, the Company will host a conference call and webcast at 4:30 p.m. ET. A live webcast of the call will be available on the Investors section of the Voyager website at ir.voyagertherapeutics.com, and a replay of the call will be available at the same link approximately two hours after its completion. The replay will be available for at least 30 days following the conclusion of the call.

    3/4/25 7:00:00 AM ET
    $VYGR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $VYGR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Voyager Therapeutics Inc.

    SC 13G/A - Voyager Therapeutics, Inc. (0001640266) (Subject)

    11/14/24 6:13:11 PM ET
    $VYGR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Voyager Therapeutics Inc.

    SC 13G/A - Voyager Therapeutics, Inc. (0001640266) (Subject)

    11/14/24 5:12:26 PM ET
    $VYGR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Voyager Therapeutics Inc.

    SC 13G/A - Voyager Therapeutics, Inc. (0001640266) (Subject)

    8/7/24 4:10:26 PM ET
    $VYGR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $VYGR
    Leadership Updates

    Live Leadership Updates

    View All

    Voyager Therapeutics Announces Appointment of Nathan Jorgensen as Chief Financial Officer

    LEXINGTON, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced the appointment of Nathan Jorgensen, Ph.D., MBA, as Chief Financial Officer (CFO), effective July 8, 2024. Jorgensen brings to Voyager a breadth of experience spanning investment banking, public and private healthcare investing, sell-side research, and operational roles in biotech, as well as expertise in neuroscience. He most recently served as Chief Financial Officer for Vor Biopharma Inc. "Voyager has built a strong financial position from which to advance our clinical-stage and emerging pipeline of neurothe

    6/13/24 7:00:00 AM ET
    $VYGR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    NorthStar Appoints Peter Pfreundschuh to Board of Managers

    NorthStar Medical Technologies, LLC, parent company of NorthStar Medical Radioisotopes, LLC, a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, today announced the appointment of Peter (Pete) Pfreundschuh to its Board of Managers, effective April 1, 2024. Following this appointment, the Board will comprise of 9 directors, 6 of whom are non-executive. "We are pleased to welcome Pete to the NorthStar Board," said Stephen Merrick, Executive Chairman of NorthStar. "Pete has deep experience in the pharmaceutical and biotechnology industry, with extensive knowledge in corporate finance, business

    4/15/24 9:00:00 AM ET
    $FREQ
    $URGN
    $VYGR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Biotechnology: In Vitro & In Vivo Diagnostic Substances

    Voyager Therapeutics Announces Appointment of Toby Ferguson as Chief Medical Officer

    LEXINGTON, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced the appointment of Toby Ferguson, M.D., Ph.D., as Chief Medical Officer (CMO), effective March 25, 2024. Ferguson is a skilled and experienced healthcare executive with a proven record in advancing portfolios of novel therapies across diverse indications in central nervous system (CNS), neuromuscular, and rare diseases. He most recently served as Vice President, Head of Neuromuscular Development Unit at Biogen, Inc. "Voyager is advancing rapidly toward the clinic, with one IND filing targeted each year through

    3/13/24 7:00:00 AM ET
    $VYGR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care